Related Experiment Video
Updated: Jul 2, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Pharmacologic therapies across the continuum of left ventricular dysfunction
William T Abraham1, Barry H Greenberg, Clyde W Yancy
1Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, Ohio 43210, USA. william.abraham@osumc.edu
The American Journal of Cardiology
|October 3, 2008
Summary
Pharmacologic therapies targeting neurohormonal activation and sympathetic stimulation improve outcomes for patients with left ventricular dysfunction (LVD) after myocardial infarction (MI). Despite guideline recommendations, these essential heart failure treatments are underutilized in post-MI LVD patients.
Area of Science:
- Cardiology
- Pharmacology
- Heart Failure Research
Background:
- Neurohormonal activation and sympathetic stimulation contribute to left ventricular dysfunction (LVD) and heart failure (HF) post-myocardial infarction (MI).
- Established pharmacologic therapies exist to counteract these detrimental pathways.
- Current guideline-recommended medications include ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists.
Purpose of the Study:
- To review the impact of guideline-recommended pharmacotherapies on post-MI LVD patients.
- To highlight evidence from clinical trials demonstrating the benefits of these therapies.
- To outline current and emerging treatments for acute decompensated heart failure.
Main Methods:
- Review of clinical trial evidence.
- Analysis of pharmacologic therapies targeting neurohormonal and sympathetic pathways.
- Examination of treatment guidelines and utilization rates.
Main Results:
- Guideline-recommended therapies show proven benefits in improving symptoms, LVD, cardiac remodeling, hospitalizations, and survival in post-MI patients.
- A significant gap exists, with over two-thirds of post-MI LVD patients not receiving these recommended treatments.
- Evidence supports the efficacy of ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists.
Conclusions:
- Pharmacologic interventions are crucial for managing post-MI LVD and improving patient outcomes.
- Underutilization of recommended therapies represents a significant clinical challenge.
- Further efforts are needed to ensure optimal implementation of evidence-based treatments for heart failure.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...